A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC)

被引：5
|
作者：
Lenz, Heinz-Josef
Kasi, Anup
Mendelsohn, Lawrence
Cannon, Timothy Lewis
Starr, Jason S.
Hubbard, Joleen M.
Bekaii-Saab, Tanios S.
Ridinger, Maya
Samuelsz, Errin
Ruffner, Katherine L.
Erlander, Mark G.
Ahn, Daniel H.
机构：
[1] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA
[2] Univ Kansas, Ctr Canc, Westwood, KS USA
[3] Little Rock Hem Onc Assoc, Little Rock, AR USA
[4] Inova Schar Canc Inst, Fairfax, VA USA
[5] Univ Florida, Hlth Canc Ctr, Jacksonville, FL USA
[6] Mayo Clin, Rochester, MN USA
[7] Mayo Clin, Div Hematol Oncol, Phoenix, AZ USA
[8] Cardiff Oncol, San Diego, CA USA
[9] Mayo Clin, Phoenix, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
100
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Early decreases in KRAS mutant allele frequency (MAF) predicts clinical benefit to the PLK1 inhibitor onvansertib in combination with FOLFIRI/bev in 2L treatment of metastatic colorectal carcinoma (mCRC)
    Lenz, H-J.
    Ridinger, M.
    Samuelsz, E.
    Smeal, T.
    Ahn, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S718 - S719
  • [2] A phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC).
    Ahn, Daniel H.
    Barzi, Afsaneh
    Ridinger, Maya
    Samuelsz, Errin
    Erlander, Mark G.
    Bekaii-Saab, Tanios S.
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] A phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal Cancer (mCRC).
    Ahn, Daniel H.
    Ridinger, Maya
    Erlander, Mark
    Bekaii-Saab, Tanios S.
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [4] Phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second line treatment of KRAS-mutated metastatic colorectal cancer
    Ahn, D. H.
    Erlander, M.
    Ridinger, M.
    Samuelsz, E.
    Barzi, A.
    Bekaii-Saab, T.
    Lenz, H. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S427 - S427
  • [5] A phase 1b/2 clinical study of onvansertib in combination with FOLFIRI/bevacizumab revealed a new role of PLK1 in regulating the hypoxia pathway in KRASmutant colorectal cancer
    Ridinger, Maya
    Karki, Anju
    Subramanian, Ramanand A.
    Samuelsz, Errin
    Yemane, Divora
    Kim, Roy
    Wu, Chu-Chiao
    Kabbinavar, Fairooz F.
    Smeal, Tod
    Lenz, Heinz-Josef
    CANCER RESEARCH, 2024, 84 (06)
  • [6] The PLK1 inhibitor onvansertib overcomes irinotecan resistance in RAS-mutated (mRAS) metastatic colorectal cancer (mCRC) in vivo and in patients (pts)
    Kopetz, S.
    Ridinger, M.
    Sorokin, A.
    Kanikarla, P.
    Gao, F.
    Liu, Z.
    Samuelsz, E.
    Smeal, T.
    Starr, J. S.
    Sharma, M. R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S704 - S704
  • [7] Expanded access program of the PLK1 inhibitor onvansertib for treatment of patients with KRAS-mutant metastatic colorectal cancer.
    Sharma, Manish R.
    Isaac, Daniel
    Ramaekers, Ryan
    Ridinger, Maya
    Erlander, Mark
    Mendelsohn, Lawrence
    CANCER RESEARCH, 2021, 81 (13)
  • [8] Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI plus /-evacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts)
    Bendell, J.
    Hubbard, J.
    O'Neil, B. H.
    Jonker, D.
    Starodub, A.
    Peyton, J.
    Pitot, H.
    Halfdanarson, T.
    Nadeau, B.
    Zubkus, J.
    Adesunloye, B.
    Edenfield, J.
    Li, Y. Z.
    Li, W.
    Grothey, A.
    Borodyansky, L.
    Li, C. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia
    Peter J P Croucher
    Maya Ridinger
    Pamela S. Becker
    Tara L. Lin
    Sandra L. Silberman
    Eunice S. Wang
    Amer M. Zeidan
    Annals of Hematology, 2023, 102 : 3049 - 3059
  • [10] Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia
    Croucher, Peter J. P.
    Ridinger, Maya
    Becker, Pamela S.
    Lin, Tara L.
    Silberman, Sandra L.
    Wang, Eunice S.
    Zeidan, Amer M.
    ANNALS OF HEMATOLOGY, 2023, 102 (11) : 3049 - 3059
12345